To further confirm the critical role of the RAGE–PI3K–AKT pathways in mediating endothelial dysfunction under high S100A9 conditions, we replaced the S100A9 inhibitor ABR‐25757 with a PI3K inhibitor (LY294002) and repeated the aforementioned endothelial functional assays. This evidence concerns the gene S100A9 and endothelial dysfunction.